West Point Optical Group and Verséa Ophthalmics Announce Partnership Supply Agreement for Biovance and Biovance 3L Ocular

West Point Optical Group (WPOG), which operates 86 Pearle Vision stores, and Verséa Ophthalmics announced that the companies have entered into a partnership supply agreement in which Verséa will be the exclusive provider of its Biovance and Biovance 3L Ocular products. The products will be the only human amniotic membrane tissue products used within WPOG practices to support the treatment of ocular surface disease and ocular surgical applications.

Financial terms of the deal were not disclosed. 

Biovance and Biovance 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix. Biovance 3L Ocular is acellular and consists of three layers of amniotic basement membrane that supports treatment of advanced ocular surface disease. As a barrier membrane, Biovance 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries. Applications include corneal and conjunctival-related injuries or defects such as corneal epithelial defects, pterygium repair, fornix reconstruction, and other procedures, many of which are relevant to WPOG practices and their eye care professional teams.

“As a corneal specialist by training, I have witnessed how innovative tissue-based ocular therapeutic interventions can drive forward innovation for ocular surface diseases,” Rob Sambursky, MD, President, Verséa Ophthalmics, said in a company news release. “Our exclusive partnership supply agreement with WPOG allows us to deliver a decellularized, ringless, advanced wound healing option to more patients, driving forward innovation for the management of ocular surface diseases.”